Company intelligence / Profile preview
Virion Therapeutics
King of Prussia, Pennsylvania, United Statesviriontx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Virion Therapeutics has initiated a first-in-human Phase 1b study of its lead candidate VRON‑0200 targeting chronic hepatitis B virus. The company reports "unprecedented preclinical data" across multiple therapeutic indications and expects multiple clinical readouts. Additional programs are advancing through IND-enabling studies for cancer indications.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- T cell-based immunotherapiesTherapeutic vaccinesGenetically encoded checkpoint modifiers (CPM)Chimeric vaccine platforms (ChiVax, ChiVax-gD)Adenoviral vectors (chimpanzee adenovirus)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Strategic partnerships with Center for Breakthrough Medicine (CDMO)contract research organizations (CROs)and other vendors.
Beyond the preview
Go deeper on Virion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virion Therapeutics.